Literature DB >> 23690787

Microarray-Based Comparisons of Ion Channel Expression Patterns: Human Keratinocytes to Reprogrammed hiPSCs to Differentiated Neuronal and Cardiac Progeny.

Leonhard Linta1, Marianne Stockmann, Qiong Lin, André Lechel, Christian Proepper, Tobias M Boeckers, Alexander Kleger, Stefan Liebau.   

Abstract

Ion channels are involved in a large variety of cellular processes including stem cell differentiation. Numerous families of ion channels are present in the organism which can be distinguished by means of, for example, ion selectivity, gating mechanism, composition, or cell biological function. To characterize the distinct expression of this group of ion channels we have compared the mRNA expression levels of ion channel genes between human keratinocyte-derived induced pluripotent stem cells (hiPSCs) and their somatic cell source, keratinocytes from plucked human hair. This comparison revealed that 26% of the analyzed probes showed an upregulation of ion channels in hiPSCs while just 6% were downregulated. Additionally, iPSCs express a much higher number of ion channels compared to keratinocytes. Further, to narrow down specificity of ion channel expression in iPS cells we compared their expression patterns with differentiated progeny, namely, neurons and cardiomyocytes derived from iPS cells. To conclude, hiPSCs exhibit a very considerable and diverse ion channel expression pattern. Their detailed analysis could give an insight into their contribution to many cellular processes and even disease mechanisms.

Entities:  

Year:  2013        PMID: 23690787      PMCID: PMC3649712          DOI: 10.1155/2013/784629

Source DB:  PubMed          Journal:  Stem Cells Int            Impact factor:   5.443


1. Introduction

Ion channels are comprised of a large variety of differing families of pore proteins. Initially, ion channels were mostly known for their role in the nervous system where they play a crucial role in the signal transmission over neurites and synapses. But in fact they are involved in numerous other cellular processes including cell size regulation, muscle contractions, immune system activation [1], or hormone release [2]. Distinct ion channels are furthermore recognized to be of high importance for excitable cells of the heart: cardiomyocytes of the working myocardium as well as cells of the cardiac conduction system. In the heart, specific ion channels are responsible, for example, for the regulated generation of action potentials and for cardiac muscle contraction strength and time [3]. Additionally, ion channels play an important role in several differentiation and maturation processes [4-6]. The presented study aims to take a closer look at ion channel expression in human-induced pluripotent stem cells (hiPSCs) to give a start point for further analyses of their distinct roles at an early developmental cell state and differentiation processes. hiPSCs are generated from somatic cells by timed overexpression of specific transcription factors and strongly resemble pluripotent embryonic stem cells [7, 8]. Pluripotency is amongst others defined by the ability to differentiate into cells of all three germ layers and unlimited symmetrical cell division. This cell system is widely utilized for studies investigating developmental processes or disease mechanisms [9, 10]. Although it has become clear that differentiation processes influence ion channel expression [11], the distinct role of ion channels during these processes is so far only poorly understood. Nevertheless, it became evident that certain ion channels play a pivotal role in stem cell biology, including cell fate determination, cell cycle regulation, or cytoskeletal reorganization [6, 12–15]. The possibilities of iPSCs include the generation of individual or patient-specific-pluripotent cells, which can be subsequently differentiated into the affected cell types. This is already utilized to study pathomechanisms in a variety of tissues and cell types [9, 16–18]. The so-called channelopathies which are based on mutations in ion channels are the cause of developmental disorders and are the subject of various studies [19, 20]. To elucidate the role of ion channels in cell differentiation, maturation or their role in pathomechanisms a well-founded knowledge of ion channel distribution in pluripotent cells, representing one of the earliest stages of development, is indispensable. In that respect, we compared the expression levels of several ion channels in human keratinocytes with their reprogrammed progeny, hiPSCs. Keratinocytes derived from plucked human hair [21, 22] represent one of the most promising cell sources for the generation of the investigated hiPSCs [23]. We have elucidated ion channel regulation for various channel families and their subtypes. Additionally, we compared the expression levels of ion channel families and subtypes, found to be regulated during reprogramming, with iPSC-differentiated progeny, namely, neurons and cardiomyocytes. These comparisons could be a start point to evaluate the contribution and function of different ion channels, for example, for self-renewal and differentiation processes in stem cells.

2. Material and Methods

2.1. Ethical Statement and Donor Information

After informed consent was given by the donors (ethical agreement by the University of Ulm, number 88/12) hair with intact hair roots was gathered by plucking from the scalp after desinfection. We used hair from healthy volunteers (age between 24 to 45 and both male and female gender).

2.2. hiPSC Generation and Cell Culture

Keratinocytes were obtained from plucked human scalp hair as already described [22]. Keratinocytes were propagated in EpiLife medium with HKGS supplement (both Invitrogen, Carlsbad, CA, USA). hiPSCs were generated from keratinocytes by lentiviral transduction of four reprogramming factors (Oct4, Sox2, Klf4, and cMyc) as described earlier [23]. After the reprogramming on rat embryonic fibroblasts they were maintained feeder-free on Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) coated dishes in mTeSR1 medium (Stemcell Technologies, Vancouver, CA, USA).

2.3. Gene Expression Microarrays

Gene expression microarrays were performed for 6 keratinocyte samples and 9 hiPSC samples with the Agilent Whole Human Genome Microarray Kit (4x44k microarray kit G4112F, Agilent Technologies, Santa Clara, CA, USA). 500 ng of total RNA was used to produce Cy3-CTP-labeled cRNA with the Agilent Low RNA Input Liner Amplification Kit. The cRNA was purified and 1,65 μg per array was hybridized for 17 h at 65°C and 10 r.p.m. Afterwards, the arrays were washed with Agilent Gene Expression Wash Buffers one and two and finally with acetonitrile for 1 min. The slides were scanned using Scan Control 7.0 software with a resolution of 5 μm. Scan data was extracted with the Feature Extraction 9.1 software. Expression levels were background adjusted and quantile normalized with the GeneSpring GX 12 software. Differential expression between keratinocytes and hiPSCs was analyzed using student's t-test. A fold change > 2 and a P value < 0.05 was considered significant and highlighted bold (upregulation) or italic (downregulation) in the results table. For comparisons of iPSCs with iPSC-derived neurons published data from GSE34879 (GSM856936, GSM856937, GSM856915, GSM856916) and for cardiomyocytes GSE17579 (GSM438022, GSM438026, GSM438034, GSM438021, GSM438032, GSM438036) were used (both from NCBI Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/). Fold change is shown if >2.

3. Results

3.1. Differential Expression of Ion Channels in hiPSCs Compared to Keratinocytes

We first compared the expression of various ion channel families from keratinocytes to hiPSCs and from hiPSCs to cardiomyocytes and neurons, respectively. From the 387 probes (Table 1) binding in ion channel genes from parental keratinocytes to hiPSCs, 101 (26%) showed a significant increase in expression (fold change > 2, P < 0.05; labeled in bold) while 23 (6%) showed a significant decrease (fold change > −2, P < 0.05; labeled in italic). In a second step differentially regulated ion channels from hiPSCs to hiPSC-derived neurons were investigated and we found 29 ion channel transcripts to be upregulated (fold change > 2; labeled in bold) while 6 showed a significant decrease (fold change > −2; labeled in italic). For cardiomyocytes, mRNA levels of only 7 ion channel members were upregulated (fold change > 2; labeled in bold) and 10 mRNA levels showed a significant decrease (fold change > −2; labeled in italic).

3.2. Voltage-Gated Calcium Channels

Voltage-gated calcium channels are crucially involved in the Ca2+-influx thereby playing an important role in calcium signaling of virtually all cells. High-voltage-gated calcium channels include the neural N-type channel, the poorly defined brain-specific R-type channel, the closely related P/Q-type channel, and the dihydropyridine-sensitive L-type channels responsible for excitation-contraction coupling of skeletal, smooth, and cardiac muscles as well as for hormone secretion in endocrine cells (reviewed in [24]). While mainly permeable for calcium ions they also show a low permeability for sodium ions. Upon depolarization of the cell they mediate a calcium influx into the cell. The channels consist of the main alpha subunit as well as regulatory beta, alpha 2/delta, and gamma subunits. The α 1 subunit forms the ion conducting pore while the associated subunits have several functions including modulation of gating [25]. CACNA1A mutations are for example involved in ataxia [26]. We have analyzed their expression with 42 probes. During reprogramming 14 (33%) of them are significantly upregulated while only 1 (2%) is significantly downregulated. From iPSCs to neurons, as expected, neuronal alpha-subunits CACNA1D, CACNA1E areupregulated together with several neuronal channel subunits (α 2 δ, β, and γ). In cardiomyocytes, solely the alpha subunit of the cardiac CACNA1C is upregulated. Of note, none of the differentiated progeny downregulated any voltage-gated calcium channels.

3.3. Sperm-Associated Cation Channels

Sperm-associated cation channels or CatSper channels are calcium ion channels. They are flagellar proteins involved in sperm motility and therefore affect fertility [27]. During reprogramming to iPSCs, from seven used probes just one showed a significant downregulation and none had a significant upregulation. We observed nothing noteworthy in the differentiated progeny.

3.4. Nicotinic Acetylcholine Receptors

Nicotinic acetylcholine receptors play a role in interneuronal synapses and neuromuscular junctions. They are composed of five subunits as homomeric or heteromeric receptors. They are located at the postsynaptic site and upon binding of acetylcholine they allow the transmission of cations, especially sodium and potassium ions, in some versions also calcium ions. This leads to a depolarization of the membrane and triggers further signaling pathways [28]. Several acetylcholine receptors and subunits are thought to play roles in a variety of pathomechanisms, for example, psychiatric disorders, cardiovascular diseases, or cancer [29-31]. From 21 probes, 5 (24%) showed a significant upregulation while 3 (14%) showed a significant downregulation from keratinocytes to iPSCs. In neurons, solely the neuronal nicotinic acetylcholine receptor CHRNA6 alpha subunit was upregulated, none in cardiomyocytes.

3.5. Cyclic Nucleotide-Gated Channels

Cyclic nucleotide-gated channels form tetrameric channels which—upon binding of cGMP—allow a flow of cations. For that, these channels track the intracellular concentration of cNMPs to produce a voltage response [32]. Their major role is the depolarization of rod photoreceptors, but they are also found in other tissues like olfactory sensory neurons [33], testis, kidney, or heart [34] and play a role in cellular development such as neuronal growth cone guidance [35]. Defects in these genes are reported to cause retinitis pigmentosa [36]. From 7 used probes one showed a significant upregulation and one showed a significant downregulation (both 14%) during reprogramming, while none was differentially regulated in differentiated neurons or cardiomyocytes.

3.6. GABA Receptors

GABA (gamma-aminobutyric acid) receptors are ligand-gated chloride channels. Since GABA is the main inhibitory neurotransmitter in the central nervous system GABA receptors play an important role for the brain function. The receptors are composed of five subunits which form heteromers. The GABA receptors are a drug target for anesthetics and other psychoactive drugs. We have analyzed 29 probes within GABA receptor subunits. From keratinocytes to iPSCs, 6 (21%) of them are significantly upregulated while just one (3%) is significantly downregulated. Interestingly, none was up- or downregulated in differentiated neurons, while GABRB3 was downregulated and GABRP was upregulated in cardiomyocytes. Up to now, more or less nothing is known about GABA receptors or their subunits in cardiac cells.

3.7. Glycine Receptors

Glycine receptors are inhibitory receptors of the postsynaptic site. They are activated by glycine and mediate an influx of chloride ions. Accordingly, GlyRs regulate not only the excitability of motor and sensory neurons but are also essential for the processing of photoreceptor signals, neuronal development, and inflammatory pain sensitization [37]. The heteromeric pore is formed by five subunits. Concerning their role in pathomechanisms, it was reported that mutations are causing hyperekplexia (also known as startle disease) [38]. We have analyzed 7 probes and none of them was significantly altered in hiPSCs. Transcript levels for the alpha2 subunit and the beta subunit were highly upregulated in differentiated neurons, pointing to their functional role in the nervous system.

3.8. Ionotropic Glutamate Receptors

Glutamate is the predominant excitatory neurotransmitter in the central nervous system. Therefore, ionotropic glutamate receptors play a key role for learning and memory processes. They are located in the postsynaptic membrane and are composed of several heteromeric subunits. Ionotropic glutamate receptors are further divided into AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate), NMDA (N-Methyl-D-aspartate) or kainate receptors depending on their sensitivity for the agonists. From 36 probes, 5 (14%) showed a significantly increased expression and 2 (6%) showed a decreased expression in iPSCs compared to keratinocytes. As expected, several subunits were upregulated in neurons (none downregulated). None was upregulated in cardiomyocytes, while the kainate subtype GRIK5 was downregulated.

3.9. Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels

Hyperpolarization-activated cyclic nucleotide-gated channels are homodimers or heterodimers and form a hyperpolarization-activated potassium channel. CNG channels display a very complex heteromeric structure with various subunits and domains that play a critical role in their function [39]. They contribute to pacemaker currents in the heart [40] but are also found in neurons [41]. We have analyzed 5 probes and 3 (60%) of them showed a significant upregulation while none was downregulated after reprogramming. In neurons the HCN3 channel transcript was upregulated, which plays a role in several neuronal functions including excitability of basal ganglia output neurons [42]. Although HCN4 for example plays a critical role in the conduction system of the heart, we did not observe a specific regulation in cardiomyocytes.

3.10. Serotonin Receptors

Serotonin (or 5-hydroxytryptamine) receptors are ligand-gated receptors mainly found presynaptically in neurons. The type 3 receptor is the only ion channel while the other serotonin receptors are G-protein-coupled receptors. It forms a heteropentameric pore which upon activation by serotonin allows the flow of sodium and potassium, leading to a depolarization. Serotonin receptors modulate neuronal function and are therefore involved in various brain functions. The analysis of 6 probes for type 3 serotonin receptors showed a significant upregulation of 2 (33%, both for HTR3A) probes while none was downregulated in hiPSCs. Although we expected serotonin receptors to be upregulated during neuronal differentiation, no subunit was upregulated in neurons or cardiomyocytes, while only the receptor transcript for HTR3A was downregulated in neurons.

3.11. Voltage-Gated Potassium Channels

Voltage-gated potassium channels are composed of a large group of subunits with different characteristics concerning for example their inactivation speed. Functional channels are formed by heterotetramers. The channels are highly specific for potassium with a low affinity for sodium or other cations. Voltage-gated potassium channels are responsible for the repolarization of excitable cells following the sodium-mediated excitation of an action potential and are therefore found in neurons and other cells displaying action potentials. We have analyzed 81 probes. From keratinocytes to hiPSCs, 25 (31%) were significantly upregulated while only 3 (4%) were significantly downregulated. In neurons, several subunits were upregulated including KCNB1, coding for Kv2.1 and KCND2, both are better known for their role in cardiac cell excitability as well as KCNF1, KCNH8, and KCNIP1, all known for their contribution in neuronal excitability [43]. It should be noted that KCNT1 is actually sodium activated but is included in the alphabetical list for a better overview. Further, several “S” subunits were upregulated (KCNS2 in neurons) or downregulated (KCNS3 in neurons; KCNS1 and 3 in cardiomyocytes). These subunits are unable to form functional channels as homotetramers but instead heterotetramerize with other alpha-subunits to form conductive channels. These subunits are involved in modifying the channels response and conductivity [44]. Few is known about distinct roles in other tissues, but they were associated with for example, pain modulation [45] or airway responsiveness [46].

3.12. Inwardly Rectifying Potassium Channels

Inwardly rectifying potassium channels have a higher tendency to allow the flow of potassium ions into the cell rather than to the outside of the cell. Therefore, they play an important role in the maintenance of the resting membrane potential. Their activation is constitutive or controlled by ATP binding and G-proteins [47]. Functional channels are formed as homo- or heterotetramers. These channels can be found predominantly in neurons, cardiac myocytes, the pancreas, or the kidneys. From 20 analyzed probes in hiPSCs compared to keratinocytes, 8 (40%) showed a significant upregulation and 3 (15%) were significantly downregulated. The GIRK2 channel encoded by KCNJ6 is upregulated in neurons playing multiple roles in various tissues including the pancreas and brain [48, 49] and is associated with epileptic seizures in mice lacking the gene [50]. On the other hand, Kir6.1, encoded by KCNJ8, is upregulated in cardiomyocytes and has been reported to be involved in the pathogenesis of cardiac arrest in the early repolarization syndrome [51].

3.13. Two-P Potassium Channels

Two-P potassium channels contain two pore-forming P domains. After dimerization they form an outward rectifying potassium channel. They can be found in several tissues and are activated by various chemical or physical means (TRAAK channels). We have analyzed 23 probes. 4 (17%) of them were significantly upregulated while 4 (17%) were significantly downregulated. In neurons KCNK3, vital for setting the resting membrane potential and primary target for volatile anesthetics [52] as well as KCNK4, which is mechanically gated and contributes to axonal pathfinding, growth cone motility, and neurite elongation, as well as possibly having a role in touch or pain detection [53, 54], were upregulated. KCNK5 and 6 were downregulated. In cardiomyocytes, downregulation of KCNK5 and 12 was observed.

3.14. Calcium-Activated Potassium Channels

Calcium-activated potassium channels are mostly activated by intracellular calcium; some family members are also voltage gated. The family consists of large, intermediate, and small conductance family members. Channels are formed by two units (KCNM family) or most commonly four units (KCNN family). They are involved in, for example, afterhyperpolarization following the action potential and are predominantly found in neurons. Additionally, they are known to play different roles in cellular mechanisms, including stem cell biology [4–6, 55]. We have analyzed 18 probes of which 9 (50%) were significantly upregulated and none was significantly downregulated after reprogramming. In neurons, solely KCNN2 was downregulated, while in cardiomyocytes KCNMA1, encoding the large conductance BK-channel, involved in heart rate regulation [56], was upregulated.

3.15. P2X Receptors

P2X receptors are receptors for extracellular ATP and upon activation open a channel for ions, predominantly calcium. The channel is formed by homo- or heterotrimers. They are found in several tissues, mainly in the nervous system and muscle tissue. They are involved in a range of physiological processes such as modulation of synaptic transmission, vascular tone, cardiac rhythm, and contractility and immune response [57-61]. In stem cells an influence of P2X receptors on embryonic stem cell proliferation was reported [62]. From the 9 analyzed probes 1 (11%) was significantly upregulated and none downregulated. None of these receptors/channels was regulated in differentiated progeny.

3.16. Transient Receptor Potential Channels

Transient receptor potential channels (TRP channels) are nonselective cation channels. They show different preferences for cations, as well as different activation mechanisms and functions. TRP channels are broadly expressed throughout the organism and mediate multiple functions. These include amongst others sensor activity for a wide range of hypertrophic stimuli and mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders (reviewed in [63]). Furthermore, TRP channels are related to the onset or progression of several diseases, and defects in the genes encoding TRP channels (so-called “TRP channelopathies”) underlie certain neurodegenerative disorders due to their abnormal Ca2+ signaling properties (reviewed in [64]). Additionally, TRP channels influence stem cell differentiation and survival [65, 66] and are involved in neuronal-stem-cell-derived development [67]. We have analyzed 40 probes. After reprogramming, 11 (28%) of them were significantly upregulated and none was significantly downregulated. In neurons, none of these channels was noteworthily regulated while solely TRPC3 was upregulated in cardiomyocytes, reported to be involved in conduction disturbances induced by adenosine receptor A1AR by enhanced Ca2+ entry through the TRPC3 channel [68].

3.17. Voltage-Gated Sodium Channels

Voltage-gated sodium channels consist of a main alpha unit and some optional modulating or regulatory subunits. They are highly selective for sodium and are involved in a variety of cellular functions including action potential formation [69]. From 24 probes we have analyzed, 6 (25%) were significantly upregulated and two (8%) were significantly downregulated from keratinocytes to iPS cells. These channels seem to be expressed in different kinds of stem cells and during development [70-72]. It was further reported that, for example, SCN5A, highly upregulated in iPS cells, is involved in cancer stem cell invasion [73]. SCN2A, SCN3A, and SCN3B were upregulated in neurons, described to be involved in neuronal excitation and epilepsy pathogenesis [74]. Although voltage-gated sodium channels play multiple roles also in the cardiac system [70, 75, 76], we observed no changes of this channel family in cardiomyocytes.

3.18. Nonvoltage-Gated Sodium Channels

Epithelial nonvoltage-gated sodium channels are amiloride sensitive. They form heterotrimers and are involved in ion and fluid transport across epithelia in several organs. We have analyzed 6 probes and one (17%) of them was significantly upregulated while none was significantly downregulated. Interestingly, the upregulated SCNN1A in iPS cells was subsequently downregulated both in neurons and cardiomyocytes, pointing to a possible function in stem cells. Of note, it was shown already that repression of pluripotency by retinoic acid represses the SCNN1A gene together with several other pluripotency factors [77].

3.19. Two-Pore Channels

Two-pore channels are cation-selective ion channels activated by the second messenger nicotinic acid adenine dinucleotide phosphate (NAADP). Upon activation calcium is released from intracellular stores [78]. We have analyzed 5 probes and while none of them was significantly upregulated two (40%) were significantly downregulated from keratinocytes to iPS cells. None of these channels was regulated in neurons or cardiomyocytes.

3.20. Zinc-Activated Ligand-Gated Ion Channels

The zinc-activated ligand-gated ion channel is activated upon binding of zinc. Until now just one family member is known that is expressed in several tissues [79]. Its exact function is not known. The expression was not significantly altered as shown by one probe in all cells.

4. Discussion

Although ion channels are mainly known for their role in electrically excitable cells they can be found in almost all tissues and are additionally involved in various processes such as cell differentiation and maturation [3, 4, 6, 12, 24, 47, 70]. These large groups of channel proteins are still underestimated concerning their role during embryonic development and cell fate determination. One of the most interesting in vitro models for the elucidation of both developmental processes and disease-specific cellular impairments is represented by pluripotent stem cells. Therefore we were interested in the set of ion channels expressed in hiPSCs after reprogramming and compared this set with iPSC-derived differentiated progeny, namely, neurons and cardiomyocytes. As little is known about ion channels in hiPSCs we aimed to start the analysis with gene expression microarray data. For a comparison, we chose the cells from which they were produced—namely, keratinocytes—as the reference cell type. The comparison of 6 keratinocyte samples with 9 hiPSC samples should minimize the often observed variances between hiPSC lines. We found out that almost a third (32%) of the ion channel probes we investigated showed a significant change in gene expression. Of note, this was mostly an upregulation. Additionally, while many ion channel genes were not expressed in keratinocytes they were present in hiPSCs. This indicates that several of the analyzed channel groups might play unknown roles in stem cell biology, for example, homeostasis, proliferation, or differentiation. Interestingly, after differentiation into neurons or cardiomyocytes, relatively small groups were subsequently regulated. This includes ion channel transcripts playing important roles in the respective tissues. Nevertheless, we compared already published sets of data from different experimental setups and additionally limited the analysis to a strong fold regulation. This might lead to high dropout rates of regulated genes during measurement. Still, various channel transcripts were “logically” up- or downregulated during differentiation into neurons or cardiomyocytes, following embryonic development. iPS cells and especially patient-specific iPS cells from persons suffering from genetic mutations leading to hereditary syndromes are a very valuable tool to investigate pathogenetic mechanisms and disease associated molecular and cellular changes [80-82]. As various channel subtypes are involved in multiple pathogenetic mechanisms it would be further interesting to analyze channel transcript regulation in patient specific iPS cells and their differentiated progeny to elucidate possible disease-specific pathways. Concerning the presented study it is clear that gene regulations on transcript level do not explicitly mimic either protein levels and posttranslational modifications or protein activity. This set of data is sought to describe a global overview on transcript regulation of ion channels during distinct steps of development. It should be noted that in cases where several probes bind within one gene they do not indicate the same upregulation. Sometimes they show the same trend but miss significance, but for some cases there are considerable differences. This could hint for some yet unknown splicing variants. More detailed studies of these hypothesized splice variants could give insights into their function and broaden the still scarce knowledge. This work is intended to be a guide and start point for future work focusing on single channels and their composition, localization, and function in hiPSCs and their differentiated progeny. These studies could lead to better in vitro differentiation protocols but also explain some of the many disease pathomechanisms related to mutations in ion channel genes.

(a) Voltage-gated calcium channels

Gene nameAccession numberGene symbol P Fold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit, transcript variant 1NM_000068CACNA1A2.26E − 01−1.32
Calcium channel, voltage-dependent, N type, alpha 1B subunitNM_000718CACNA1B7.27E − 01−1.10
Calcium channel, voltage-dependent, N type, alpha 1B subunit [Source: HGNC Symbol; Acc: 1389]ENST00000277550CACNA1B7.15E − 01−1.14
Calcium channel, voltage-dependent, N type, alpha 1B subunitNM_000718CACNA1B6.32E − 09 6.82
Calcium channel, voltage-dependent, N type, alpha 1B subunit [Source: HGNC Symbol; Acc: 1389]ENST00000277551CACNA1B3.32E − 02−1.57
Calcium channel, voltage-dependent, L type, alpha 1C subunit, transcript variant 18NM_000719CACNA1C6.77E − 02−1.37
Calcium channel, voltage-dependent, L type, alpha 1C subunit, transcript variant 18NM_000719CACNA1C5.72E − 03 2.37 2.94
Calcium channel, voltage-dependent, L type, alpha 1D subunit, transcript variant 1NM_000720CACNA1D3.83E − 011.58
Calcium channel, voltage-dependent, R type, alpha 1E subunit, transcript variant 3NM_000721CACNA1E 3.10 E02 −4.48 2.08
Calcium channel, voltage-dependent, R type, alpha 1E subunit [Source: HGNC Symbol; Acc: 1392]ENST00000524607CACNA1E8.83E − 011.05
Calcium channel, voltage-dependent, L type, alpha 1F subunitNM_005183CACNA1F8.92E − 011.02
Calcium channel, voltage-dependent, T type, alpha 1G subunit, transcript variant 15NM_198397CACNA1G6.42E − 01−1.12 4.60
Calcium channel, voltage-dependent, T type, alpha 1G subunit, transcript variant 1NM_018896CACNA1G5.37E − 07 6.96
Calcium channel, voltage-dependent, T type, alpha 1H subunit, transcript variant 1NM_021098CACNA1H7.38E − 10 6.78
Calcium channel, voltage-dependent, T type, alpha 1I subunit, transcript variant 1NM_021096CACNA1I2.22E − 11 37.25
Calcium channel, voltage-dependent, T type, alpha 1I subunit, transcript variant 1NM_021096CACNA1I7.56E − 02−1.56
Calcium channel, voltage-dependent, L type, alpha 1S subunitNM_000069CACNA1S5.22E − 02−1.97
Calcium channel, voltage-dependent, alpha 2/delta subunit 1NM_000722CACNA2D11.38E − 09 9.65
Calcium channel, voltage-dependent, alpha 2/delta subunit 2, transcript variant 1NM_001005505CACNA2D23.30E − 10 62.50 2.02
Calcium channel, voltage-dependent, alpha 2/delta subunit 3NM_018398CACNA2D35.14E − 05 5.42 2.55
Calcium channel, voltage-dependent, alpha 2/delta subunit 3AF516696CACNA2D34.68E − 11 33.67
Calcium channel, voltage-dependent, alpha 2/delta subunit 4NM_172364CACNA2D42.95E − 01−1.41
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 3NM_199248CACNB1 4.31E − 01−1.14
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 1NM_000723CACNB18.02E − 01−1.02
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 1NM_000723CACNB16.22E − 011.04
cDNA FLJ45229 fis, clone BRCAN2020972, AK128769CACNB29.78E − 011.02
Calcium channel, voltage-dependent, beta 2 subunit, transcript variant 1NM_000724CACNB24.71E − 02 3.45
Calcium channel, voltage-dependent, beta 3 subunit, transcript variant 1NM_000725CACNB33.55E − 02−1.93 9.56
Calcium channel, voltage-dependent, beta 3 subunit, transcript variant 1NM_000725CACNB36.61E − 011.09
Calcium channel, voltage-dependent, beta 4 subunit, transcript variant 1NM_001005747CACNB41.33E − 03 4.43
Calcium channel, voltage-dependent, gamma subunit 1NM_000727CACNG19.46E − 011.02
Calcium channel, voltage-dependent, gamma subunit 2NM_006078CACNG24.19E − 01−1.29
Calcium channel, voltage-dependent, gamma subunit 2NM_006078CACNG27.91E − 011.09
Calcium channel, voltage-dependent, gamma subunit 3NM_006539CACNG32.21E − 01−1.95
Calcium channel, voltage-dependent, gamma subunit 4NM_014405CACNG44.93E − 011.14
Calcium channel, voltage-dependent, gamma subunit 5NM_145811CACNG57.49E − 01−1.13
Calcium channel, voltage-dependent, gamma subunit 5 [Source: HGNC Symbol; Acc: 1409]ENST00000169565CACNG52.19E − 01−1.56
Calcium channel, voltage-dependent, gamma subunit 6, transcript variant 1NM_145814CACNG65.56E − 11 46.40
Calcium channel, voltage-dependent, gamma subunit 7NM_031896CACNG73.54E − 13 1439.36 3.37
Calcium channel, voltage-dependent, gamma subunit 7NM_031896CACNG71.82E − 011.26
Calcium channel, voltage-dependent, gamma subunit 8NM_031895CACNG82.01E − 011.43
Calcium channel, voltage-dependent, gamma subunit 8NM_031895CACNG81.18E − 09 9.70

(b) Sperm-associated cation channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Cation channel, sperm associated 1NM_053054CATSPER13.26E − 011.51
Cation channel, sperm associated 2, transcript variant 2NM_172095CATSPER2 1.32 E04 −2.78
Cation channel, sperm associated 2, transcript variant 4NM_172097CATSPER23.12E − 02−1.78
Cation channel, sperm associated 3NM_178019CATSPER31.50E − 031.93
Cation channel, sperm associated 4NM_198137CATSPER42.51E − 011.48
Cation channel, sperm-associated, betaNM_024764CATSPERB4.38E − 01−1.25
Cation channel, sperm-associated, gammaNM_021185CATSPERG3.56E − 011.34

(c) Nicotinic acetylcholine receptors

Gene nameAccession numberGene symbolPFold changeKer → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Cholinergic receptor, nicotinic, alpha 1 (muscle), transcript variant 1NM_001039523CHRNA18.06E − 01−1.10
Cholinergic receptor, nicotinic, alpha 1 (muscle), (cDNA clone IMAGE: 4124038), with apparent retained intronBC006314CHRNA14.64E − 011.47
Cholinergic receptor, nicotinic, alpha 2 (neuronal)NM_000742CHRNA26.05E − 01−1.30
Cholinergic receptor, nicotinic, alpha 3, transcript variant 1NM_000743CHRNA31.84E − 10 34.22
Cholinergic receptor, nicotinic, alpha 4NM_000744CHRNA46.79E − 011.15
Cholinergic receptor, nicotinic, alpha 4 (neuronal), exon 1X89741CHRNA4 2.79 E02 −2.53
Cholinergic receptor, nicotinic, alpha 5NM_000745CHRNA54.03E − 05 3.41
Cholinergic receptor, nicotinic, alpha 6, transcript variant 1NM_004198CHRNA62.23E − 01−1.27 2.21
Cholinergic receptor, nicotinic, alpha 7, transcript variant 1NM_000746CHRNA74.61E − 041.86
Cholinergic receptor, nicotinic, alpha 7, transcript variant 2NM_001190455CHRNA71.56E − 1113.24
Cholinergic receptor, nicotinic, alpha 9NM_017581CHRNA96.30E − 06 6.15
Cholinergic receptor, nicotinic, alpha 10NM_020402CHRNA101.57E − 021.57
Cholinergic receptor, nicotinic, beta 1 (muscle)NM_000747CHRNB1 8.07 E04 −2.47
Cholinergic receptor, nicotinic, beta 1 (muscle)NM_000747CHRNB18.87E − 03−1.92
Cholinergic receptor, nicotinic, beta 2 (neuronal)NM_000748CHRNB2 6.03 E04 −3.01
Cholinergic receptor, nicotinic, beta 2 (neuronal) [Source: HGNC Symbol; Acc: 1962]ENST00000368476CHRNB22.98E − 09 32.05
Cholinergic receptor, nicotinic, beta 3NM_000749CHRNB35.91E − 011.12
Cholinergic receptor, nicotinic, beta 4NM_000750CHRNB41.76E − 02 4.20
Cholinergic receptor, nicotinic, deltaNM_000751CHRND9.84E − 011.01
Cholinergic receptor, nicotinic, epsilonNM_000080CHRNE3.66E − 01−1.20
Cholinergic receptor, nicotinic, gammaNM_005199CHRNG6.70E − 011.14

(d) Cyclic nucleotide-gated channels

Gene nameAccession numberGene symbolPFold changeKer → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Cyclic nucleotide-gated channel alpha 1, transcript variant 2NM_000087CNGA17.14E − 011.15
Cyclic nucleotide-gated channel alpha 1, transcript variant 2NM_000087CNGA11.18E − 022.00
Cyclic nucleotide-gated channel alpha 3, transcript variant 1NM_001298CNGA32.00E − 011.21
Cyclic nucleotide-gated channel alpha 4NM_001037329CNGA42.78E − 011.82
Cyclic nucleotide-gated channel beta 1, transcript variant 1NM_001297CNGB1 9.22 E03 −2.05
Cyclic nucleotide-gated channel beta 1, transcript variant 1NM_001297CNGB16.36E − 01−1.13
Cyclic nucleotide-gated channel beta 3NM_019098CNGB32.93E − 011.78

(e) GABA receptors

Gene nameAccession numberGene symbolPFold changeKer → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Gamma-aminobutyric acid (GABA) A receptor, alpha 1, transcript variant 1NM_000806GABRA11.26E − 011.41
Gamma-aminobutyric acid (GABA) A receptor, alpha 1, transcript variant 1NM_000806GABRA18.87E − 011.05
Gamma-aminobutyric acid (GABA) A receptor, alpha 2, transcript variant 1NM_000807GABRA29.70E − 021.70
Gamma-aminobutyric acid (GABA) A receptor, alpha 2, transcript variant 1NM_000807GABRA24.49E − 011.48
Gamma-aminobutyric acid (GABA) A receptor, alpha 3NM_000808GABRA32.10E − 011.43
Gamma-aminobutyric acid (GABA) A receptor, alpha 4, transcript variant 1NM_000809GABRA43.76E − 011.43
Gamma-aminobutyric acid (GABA) A receptor, alpha 4, transcript variant 1NM_000809GABRA48.30E − 011.05
Gamma-aminobutyric acid (GABA) A receptor, alpha 5, transcript variant 1NM_000810GABRA51.09E − 08 14.41
Gamma-aminobutyric acid (GABA) A receptor, alpha 6NM_000811GABRA61.69E − 011.23
Gamma-aminobutyric acid (GABA) A receptor, beta 1NM_000812GABRB11.14E − 011.43
Gamma-aminobutyric acid (GABA) A receptor, beta 2, transcript variant 2NM_000813GABRB21.27E − 021.94
Gamma-aminobutyric acid (GABA) A receptor, beta 3, transcript variant 1NM_000814GABRB36.70E − 10 85.93 −4.49
Gamma-aminobutyric acid (GABA) A receptor, beta 3, transcript variant 1NM_000814GABRB31.15E − 09 115.69
Gamma-aminobutyric acid (GABA) A receptor, deltaNM_000815GABRD6.26E − 023.02
Gamma-aminobutyric acid (GABA) A receptor, epsilonNM_004961GABRE 5.83 E05 −5.47
Gamma-aminobutyric acid (GABA) A receptor, Gamma 1NM_173536GABRG11.78E − 011.24
Gamma-aminobutyric acid (GABA) A receptor, Gamma 1NM_173536GABRG11.70E − 02 2.19
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 1NM_198904GABRG26.02E − 011.14
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 2NM_000816GABRG25.28E − 021.72
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 2NM_000816GABRG29.47E − 09 8.41
Gamma-aminobutyric acid (GABA) A receptor, Gamma 3NM_033223GABRG31.99E − 012.00
Gamma-aminobutyric acid (GABA) A receptor, Gamma 3NM_033223GABRG31.04E − 011.61
Gamma-aminobutyric acid (GABA) A receptor, piNM_014211GABRP6.62E − 01−1.12 17.25
Gamma-aminobutyric acid (GABA) receptor, thetaNM_018558GABRQ1.60E − 011.56
Gamma-aminobutyric acid (GABA) receptor, thetaNM_018558GABRQ4.76E − 01−1.27
Gamma-aminobutyric acid (GABA) receptor, theta [Source: HGNC Symbol; Acc: 14454]ENST00000370306GABRQ8.22E − 09 52.17
Gamma-aminobutyric acid (GABA) receptor, rho 1NM_002042GABRR18.94E − 01−1.04
Gamma-aminobutyric acid (GABA) receptor, rho 2NM_002043GABRR22.83E − 011.54
Gamma-aminobutyric acid (GABA) receptor, rho 3NM_001105580GABRR33.05E − 01−1.34

(f) Glycine receptors

Gene nameAccession numberGene symbolPFold changeKer → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Glycine receptor, alpha 1, transcript variant 2NM_000171GLRA15.47E − 01−1.29
Glycine receptor, alpha 2, transcript variant 1NM_002063GLRA21.17E − 011.42 11.41
Glycine receptor, alpha 3, transcript variant 1NM_006529GLRA35.16E − 01−1.26
Glycine receptor, alpha 3 [Source: HGNC Symbol; Acc: 4328]ENST00000274093GLRA38.33E − 021.64
Glycine receptor, alpha 3, transcript variant 1NM_006529GLRA31.46E − 011.41
Glycine receptor, alpha 4, transcript variant 1NM_001024452GLRA47.75E − 011.17
Glycine receptor, beta, transcript variant 1NM_000824GLRB6.38E − 02−1.69 6.61

(g) Ionotropic glutamate receptors

Gene nameAccession numberGene symbolPFold changeKer → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Glutamate receptor, ionotropic, AMPA 1, transcript variant 1NM_000827GRIA17.65E − 01−1.20 2.06
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1NM_000826GRIA22.87E − 01−1.87 21.26
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1NM_000826GRIA22.72E − 011.33
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1NM_000826GRIA26.54E − 011.22
Glutamate receptor, ionotropic, AMPA 3, transcript variant 2NM_000828GRIA35.05E − 011.26
Glutamate receptor, ionotropic, AMPA 3 [Source: HGNC Symbol; Acc: 4573]ENST00000371264GRIA31.14E − 011.50
Glutamate receptor, ionotropic, AMPA 3, transcript variant 2NM_000828GRIA39.05E − 01−1.05
Glutamate receptor, ionotropic, AMPA 4, transcript variant 1NM_000829GRIA42.30E − 021.80 3.73
Glutamate receptor, ionotropic, delta 1NM_017551GRID11.82E − 011.50
Glutamate receptor, ionotropic, delta 1NM_017551GRID15.08E − 05 3.63
Glutamate receptor, ionotropic, delta 2NM_001510GRID27.64E − 01−1.11
Glutamate receptor, ionotropic, delta 2NM_001510GRID25.55E − 09 55.66
Glutamate receptor, ionotropic, kainate 1, transcript variant 1NM_000830GRIK11.64E − 011.29 2.58
Glutamate receptor, ionotropic, kainate 2, transcript variant 3NM_001166247GRIK21.42E − 011.56 2.53
Glutamate receptor, ionotropic, kainate 2, transcript variant 1NM_021956GRIK21.14E − 01−2.01
Glutamate receptor, ionotropic, kainate 2, transcript variant 2NM_175768GRIK27.80E − 011.08
Glutamate receptor, ionotropic, kainate 3NM_000831GRIK31.58E − 011.64
Glutamate receptor, ionotropic, kainate 3NM_000831GRIK36.15E − 10 22.64
Glutamate receptor, ionotropic, kainate 4 [Source: HGNC Symbol; Acc: 4582]ENST00000527524GRIK41.77E − 11 18.10
Glutamate receptor, ionotropic, kainate 4NM_014619GRIK45.73E − 022.54
Glutamate receptor, ionotropic, kainate 5NM_002088GRIK52.65E − 031.79 −2.41
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3NM_007327GRIN1 1.93 E02 −3.02 2.69
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3NM_007327GRIN16.01E − 02−2.45
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3NM_007327GRIN13.86E − 01−1.65
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2NM_000833GRIN2A6.54E − 011.18
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2NM_000833GRIN2A9.21E − 01−1.02
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 1NM_001134407GRIN2A3.32E − 10 29.85
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2NM_000833GRIN2A2.63E − 011.55
Glutamate receptor, ionotropic, N-methyl D-aspartate 2BNM_000834GRIN2B6.64E − 01−1.26
Glutamate receptor, ionotropic, N-methyl D-aspartate 2CNM_000835GRIN2C8.01E − 01−1.08
Glutamate receptor, ionotropic, N-methyl D-aspartate 2CNM_000835GRIN2C5.01E − 011.13
Glutamate receptor, ionotropic, N-methyl D-aspartate 2DNM_000836GRIN2D4.69E − 02−1.82
Glutamate receptor, ionotropic, N-methyl-D-aspartate 3ANM_133445GRIN3A3.28E − 01−1.41
Glutamate receptor, ionotropic, N-methyl-D-aspartate 3BNM_138690GRIN3B9.36E − 01−1.02
Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding), transcript variant 1NM_000837GRINA 3.68 E04 −2.05 2.05
NMDA receptor glutamate-binding chain (hnrgw), partialU44954GRINA3.06E − 04−1.81

(h) Hyperpolarization-activated cyclic nucleotide-gated channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1NM_021072HCN13.47E − 11 52.85
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1NM_021072HCN11.01E − 08 9.91
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 2NM_001194HCN25.36E − 02−1.63
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 3NM_020897HCN31.98E − 02 2.12 6.56
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 4NM_005477HCN41.01E − 01−1.66

(i) Serotonin receptors

Gene nameAccession numberGene symbol P Fold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
5-hydroxytryptamine (serotonin) receptor 3A, transcript variant 1NM_213621HTR3A1.99E − 03 2.77 −2.20
5-hydroxytryptamine (serotonin) receptor 3A, transcript variant 1NM_213621HTR3A2.63E − 11 11.11
5-hydroxytryptamine (serotonin) receptor 3BNM_006028HTR3B1.99E − 01−1.54
5-hydroxytryptamine (serotonin) receptor 3, family member CNM_130770HTR3C4.81E − 011.34
5-hydroxytryptamine (serotonin) receptor 3 family member D, transcript variant 2NM_182537HTR3D4.75E − 01−1.37
5-hydroxytryptamine (serotonin) receptor 3, family member ENM_182589HTR3E1.52E − 01−1.44

(j) Voltage-gated potassium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold changehiPSC → NeuronFold change hiPSC → CM
Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)NM_000217KCNA11.64E − 012.00
Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)NM_000217KCNA11.31E − 011.87
Potassium voltage-gated channel, shaker-related subfamily, member 2, transcript variant 2NM_001204269KCNA28.55E − 021.33
Potassium voltage-gated channel, shaker-related subfamily, member 2, transcript variant 1NM_004974KCNA28.33E − 011.06
Potassium voltage-gated channel, shaker-related subfamily, member 3NM_002232KCNA32.43E − 011.76
Potassium voltage-gated channel, shaker-related subfamily, member 4NM_002233KCNA45.75E − 011.11
Potassium voltage-gated channel, shaker-related subfamily, member 5NM_002234KCNA51.76E − 04 4.11 5.63
Potassium voltage-gated channel, shaker-related subfamily, member 6NM_002235KCNA67.20E − 022.28
Potassium voltage-gated channel, shaker-related subfamily, member 7NM_031886KCNA78.53E − 03 3.67
Potassium voltage-gated channel, shaker-related subfamily, member 7NM_031886KCNA71.04E − 012.39
Potassium voltage-gated channel, shaker-related subfamily, member 10NM_005549KCNA103.32E − 01−1.62
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2NM_003471KCNAB12.70E − 011.46
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2NM_003471KCNAB13.60E − 02 2.42
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2NM_003471KCNAB17.87E − 023.06
Potassium voltage-gated channel, shaker-related subfamily, beta member 2, transcript variant 1NM_003636KCNAB25.35E − 01−1.35
Potassium voltage-gated channel, shaker-related subfamily, beta member 2, transcript variant 1NM_003636KCNAB22.20E − 011.26
Potassium voltage-gated channel, shaker-related subfamily, beta member 3 [Source: HGNC Symbol; Acc: 6230]ENST00000303790KCNAB38.14E − 021.62
Potassium voltage-gated channel, shaker-related subfamily, beta member 3NM_004732KCNAB33.66E − 011.35
Potassium voltage-gated channel, Shab-related subfamily, member 1NM_004975KCNB17.42E − 08 16.32 2.59
Potassium voltage-gated channel, Shab-related subfamily, member 2NM_004770KCNB21.54E − 05 4.58
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant ANM_001112741KCNC11.47E − 011.75
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant BNM_004976KCNC14.86E − 08 13.97
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant ANM_001112741KCNC12.17E − 011.56
Potassium voltage-gated channel, Shaw-related subfamily, member 2, transcript variant 1NM_139136KCNC28.53E − 011.06
Potassium voltage-gated channel, Shaw-related subfamily, member 2, transcript variant 2NM_139137KCNC24.04E − 011.34
Potassium voltage-gated channel, Shaw-related subfamily, member 3NM_004977KCNC33.56E − 011.20
Potassium voltage-gated channel, Shaw-related subfamily, member 4, transcript variant 3NM_001039574KCNC47.70E − 02−1.40
Potassium voltage-gated channel, Shal-related subfamily, member 1NM_004979KCND11.48E − 04 7.11
Potassium voltage-gated channel, Shal-related subfamily, member 2NM_012281KCND21.62E − 12 91.08 2.76 −2.57
Potassium voltage-gated channel, Shal-related subfamily, member 2NM_012281KCND22.76E − 09 21.83
Potassium voltage-gated channel, Shal-related subfamily, member 3 [Source: HGNC Symbol; Acc: 6239]ENST00000369697KCND35.36E − 01−1.36
Potassium voltage-gated channel, Shal-related subfamily, member 3, transcript variant 1NM_004980KCND31.05E − 011.55
Potassium voltage-gated channel, Shal-related subfamily, member 3, transcript variant 1NM_004980KCND34.41E − 011.37
Potassium voltage-gated channel, Shal-related subfamily, member 3 [Source: HGNC Symbol; Acc: 6239]ENST00000369697KCND33.86E − 04−1.84
Potassium voltage-gated channel, Isk-related family, member 1, transcript variant 2NM_000219KCNE13.53E − 01−1.45
Potassium voltage-gated channel, Isk-related family, member 1, transcript variant 2NM_000219KCNE13.59E − 011.25
KCNE1-likeNM_012282KCNE1L1.34E − 08 4.44 −2.18
KCNE1-likeNM_012282KCNE1L1.11E − 08 3.65
KCNE1-likeNM_012282KCNE1L6.41E − 031.88
Potassium voltage-gated channel, Isk-related family, member 2NM_172201KCNE21.41E − 04 3.93
Potassium voltage-gated channel, Isk-related family, member 3NM_005472KCNE38.65E − 15 52.36
Potassium voltage-gated channel, Isk-related family, member 4NM_080671KCNE45.04E − 011.20
Potassium voltage-gated channel, subfamily F, member 1NM_002236KCNF12.25E − 05 6.48 2.84
Potassium voltage-gated channel, subfamily G, member 1NM_002237KCNG18.51E − 03−1.82
Potassium voltage-gated channel, subfamily G, member 1NM_002237KCNG11.55E − 01−1.65
Potassium voltage-gated channel, subfamily G, member 2NM_012283KCNG26.21E − 021.32
Potassium voltage-gated channel, subfamily G, member 3, transcript variant 1NM_133329KCNG33.74E − 11 58.95 −2.93
Potassium voltage-gated channel, subfamily G, member 4NM_172347KCNG4 3.36 E03 −3.33
Potassium voltage-gated channel, subfamily G, member 4, (cDNA clone IMAGE: 3028985)BC008969KCNG4 2.24 E04 −3.29
Potassium voltage-gated channel, subfamily H (eag-related), member 1, transcript variant 1NM_172362KCNH18.05E − 01−1.15
Potassium voltage-gated channel, subfamily H (eag-related), member 2, transcript variant 1NM_000238KCNH25.94E − 04 37.53
Potassium voltage-gated channel, subfamily H (eag-related), member 2, transcript variant 2NM_172056KCNH25.70E − 031.73
Potassium voltage-gated channel, subfamily H (eag-related), member 3NM_012284KCNH39.65E − 011.01
Potassium voltage-gated channel, subfamily H (eag-related), member 4NM_012285KCNH43.18E − 01−1.24
Potassium voltage-gated channel, subfamily H (eag-related), member 5, transcript variant 2NM_172376KCNH53.04E − 03 2.96
Potassium voltage-gated channel, subfamily H (eag-related), member 5, transcript variant 1NM_139318KCNH55.41E − 011.47
Potassium voltage-gated channel, subfamily H (eag-related), member 6, transcript variant 2NM_173092KCNH62.93E − 02 3.04
cDNA FLJ33650 fis, clone BRAMY2024514, highly similar to Rattus norvegicus Potassium channel (erg2)AK090969KCNH62.08E − 05 12.42
Potassium voltage-gated channel, subfamily H (eag-related), member 6, transcript variant 2NM_173092KCNH62.55E − 02 2.29
Potassium voltage-gated channel, subfamily H (eag-related), member 7, transcript variant 2NM_173162KCNH74.63E − 01−1.40
Potassium voltage-gated channel, subfamily H (eag-related), member 7, transcript variant 1NM_033272KCNH77.58E − 01−1.09
Potassium voltage-gated channel, subfamily H (eag-related), member 8NM_144633KCNH83.00E − 09 24.57 2.97
Kv channel interacting protein 1, transcript variant 1NM_001034837KCNIP18.33E − 021.96 4.24
Kv channel interacting protein 2, transcript variant 7NM_173197KCNIP26.43E − 011.21
Kv channel interacting protein 2, transcript variant 1NM_014591KCNIP22.53E − 031.96
Kv channel interacting protein 3, calsenilin, transcript variant 1NM_013434KCNIP3 1.15 E03 −3.47
Kv channel interacting protein 4, transcript variant 5NM_001035003KCNIP46.73E − 011.16 2.01
Kv channel interacting protein 4, transcript variant 5NM_001035003KCNIP49.26E − 011.05
Potassium voltage-gated channel, KQT-like subfamily, member 1, transcript variant 1NM_000218KCNQ13.31E − 09 79.52
Potassium voltage-gated channel, KQT-like subfamily, member 2, transcript variant 5NM_172109KCNQ25.68E − 19 3408.43
Potassium voltage-gated channel, KQT-like subfamily, member 2, transcript variant 3NM_004518KCNQ21.29E − 021.82
Potassium voltage-gated channel, KQT-like subfamily, member 2, (cDNA clone IMAGE: 4154700)BC020384KCNQ21.09E − 08 37.12
Potassium voltage-gated channel, KQT-like subfamily, member 3, transcript variant 1NM_004519KCNQ31.10E − 04−1.69
Potassium voltage-gated channel, KQT-like subfamily, member 4, transcript variant 1NM_004700KCNQ49.77E − 011.02
Potassium voltage-gated channel, KQT-like subfamily, member 5, transcript variant 1NM_019842KCNQ59.81E − 02−1.79
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1NM_002251KCNS13.39E − 01−1.27 −2.64
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2NM_020697KCNS26.19E − 02−2.45 2.11
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3NM_002252KCNS31.04E − 04 2.22 −2.61 −2.39
Potassium channel, subfamily T, member 1 (sodium activated)NM_020822KCNT18.51E − 02−2.17
Potassium channel, subfamily V, member 1NM_014379KCNV17.84E − 021.58
Potassium channel, subfamily V, member 2NM_133497KCNV27.63E − 01−1.16

(k) Inwardly rectifying potassium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Potassium inwardly-rectifying channel, subfamily J, member 1, transcript variant rom-k5NM_153767KCNJ12.54E − 02 2.66
Potassium inwardly-rectifying channel, subfamily J, member 1, transcript variant rom-k5NM_153767KCNJ18.51E − 01−1.05
Potassium inwardly-rectifying channel, subfamily J, member 2NM_000891KCNJ25.14E − 04 4.38
Potassium inwardly-rectifying channel, subfamily J, member 3NM_002239KCNJ34.56E − 011.34
Potassium inwardly-rectifying channel, subfamily J, member 4, transcript variant 1NM_152868KCNJ44.80E − 02 2.30
Potassium inwardly-rectifying channel, subfamily J, member 5NM_000890KCNJ5 1.88 E08 −45.40
Potassium inwardly-rectifying channel, subfamily J, member 5NM_000890KCNJ5 4.42 E12 −109.11
Potassium inwardly-rectifying channel, subfamily J, member 6NM_002240KCNJ63.29E − 05 6.75 5.54
Potassium inwardly-rectifying channel, subfamily J, member 8NM_004982KCNJ81.98E − 04 5.97 2.74
Potassium inwardly-rectifying channel, subfamily J, member 9 [Source: HGNC Symbol; Acc: 6270]ENST00000368088KCNJ93.17E − 011.49
Potassium inwardly-rectifying channel, subfamily J, member 9NM_004983KCNJ93.07E − 011.79
Potassium inwardly-rectifying channel, subfamily J, member 10NM_002241KCNJ108.85E − 04 4.14
Potassium inwardly-rectifying channel, subfamily J, member 10NM_002241KCNJ109.56E − 011.01
Potassium inwardly-rectifying channel, subfamily J, member 11, transcript variant 1NM_000525KCNJ114.00E − 04 2.93
Potassium inwardly-rectifying channel, subfamily J, member 12NM_021012KCNJ121.00E − 011.47
Potassium inwardly-rectifying channel, subfamily J, member 12NM_021012KCNJ123.53E − 06 5.81
Potassium inwardly-rectifying channel, subfamily J, member 13, transcript variant 1NM_002242KCNJ137.75E − 011.20
Potassium inwardly-rectifying channel, subfamily J, member 14, transcript variant 2NM_170720KCNJ149.05E − 02−1.40
Potassium inwardly-rectifying channel, subfamily J, member 15, transcript variant 1NM_170736KCNJ15 3.41 E08 −150.95
Potassium inwardly-rectifying channel, subfamily J, member 16, transcript variant 2NM_170741KCNJ162.22E − 01−1.93

(l) Two-P potassium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Potassium channel, subfamily K, member 1NM_002245KCNK13.02E − 04−1.68
Potassium channel, subfamily K, member 2, transcript variant 1NM_001017424KCNK23.46E − 011.57
Potassium channel, subfamily K, member 3NM_002246KCNK39.98E − 011.00 2.36
Potassium channel, subfamily K, member 3NM_002246KCNK38.75E − 01−1.10
Potassium channel, subfamily K, member 3NM_002246KCNK35.34E − 01−1.30
Potassium channel, subfamily K, member 3 [Source: HGNC Symbol; Acc: 6278]ENST00000302909KCNK32.53E − 011.52
Potassium channel, subfamily K, member 4NM_033310KCNK46.21E − 01−1.14 2.05
Potassium channel, subfamily K, member 5NM_003740KCNK51.16E − 14 29.46 −2.35 −2.03
Potassium channel, subfamily K, member 6NM_004823KCNK6 1.22 E06 −3.48 −2.20
Potassium channel, subfamily K, member 6NM_004823KCNK6 2.05 E08 −5.11
Potassium channel, subfamily K, member 6NM_004823KCNK6 7.04E−06 −5.22
Potassium channel, subfamily K, member 7, transcript variant ANM_033347KCNK71.17E − 01−1.52
Potassium channel, subfamily K, member 9NM_016601KCNK96.67E − 01−1.29
Potassium channel, subfamily K, member 10, transcript variant 1NM_021161KCNK102.63E − 01−1.30
Potassium channel, subfamily K, member 10, transcript variant 2NM_138317KCNK101.41E − 021.43
Potassium channel, subfamily K, member 12NM_022055KCNK124.58E − 10 23.40 −5.58
Potassium channel, subfamily K, member 13NM_022054KCNK137.65E − 01−1.10
Potassium channel, subfamily K, member 15NM_022358KCNK154.96E − 02−1.50
Potassium channel, subfamily K, member 15NM_022358KCNK159.10E − 01−1.09
Pancreatic potassium channel TALK-1d; alternatively splicedAY253147KCNK16 2.17 E02 −2.43
Potassium channel, subfamily K, member 17, transcript variant 1NM_031460KCNK171.87E − 11 28.60
Potassium channel, subfamily K, member 17, transcript variant 1NM_031460KCNK171.52E − 05 19.62
Potassium channel, subfamily K, member 18NM_181840KCNK181.77E − 011.61

(m) Calcium-activated potassium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2NM_002247KCNMA11.01E − 021.84 2.01
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 1NM_001014797KCNMA13.19E − 011.32
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2NM_002247KCNMA13.67E − 03 2.27
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2NM_002247KCNMA18.53E − 021.44
Maxi-K channel HSLOAF349445KCNMA13.04E − 011.44
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2NM_002247KCNMA12.15E − 01−1.23
Potassium large conductance calcium-activated channel, subfamily M, beta member 1NM_004137KCNMB17.12E − 02−1.41
Potassium large conductance calcium-activated channel, subfamily M, beta member 1NM_004137KCNMB12.23E − 06 7.82
Potassium large conductance calcium-activated channel, subfamily M, beta member 2, transcript variant 1NM_181361KCNMB23.36E − 011.56
Potassium large conductance calcium-activated channel, subfamily M, beta member 2, transcript variant 1NM_181361KCNMB21.17E − 011.47
Potassium large conductance calcium-activated channel, subfamily M beta member 3, transcript variant 1NM_171828KCNMB31.41E − 05 2.63
Potassium large conductance calcium-activated channel, subfamily M, beta member 4NM_014505KCNMB48.85E − 12 103.99
Potassium large conductance calcium-activated channel, subfamily M, beta member 4 [Source: HGNC Symbol; Acc: 6289]ENST00000258111KCNMB49.22E − 10 18.40
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1NM_002248KCNN13.40E − 05 4.67
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2, transcript variant 1NM_021614KCNN21.88E − 13 22.23 −3.63
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3, transcript variant 1NM_002249KCNN32.58E − 06 8.25
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3, transcript variant 3NM_001204087KCNN31.11E − 07 15.29
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4NM_002250KCNN41.06E − 02−1.84

(n) P2X receptors

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Purinergic receptor P2X, ligand-gated ion channel, 1NM_002558P2RX17.71E − 011.14
Purinergic receptor P2X, ligand-gated ion channel, 2, transcript variant 4NM_170683P2RX25.25E − 02−1.66
Purinergic receptor P2X, ligand-gated ion channel, 3NM_002559P2RX32.43E − 02−1.76
Purinergic receptor P2X, ligand-gated ion channel, 4NM_002560P2RX48.68E − 01−1.03
Purinergic receptor P2X, ligand-gated ion channel, 5, transcript variant 1NM_002561P2RX57.68E − 08 6.97
Purinergic receptor P2X, ligand-gated ion channel, 5, transcript variant 2NM_175080P2RX56.13E − 021.54
Purinergic receptor P2X, ligand-gated ion channel, 6 [Source: HGNC Symbol; Acc: 8538]ENST00000413302P2RX64.13E − 011.68
Purinergic receptor P2X, ligand-gated ion channel, 7, transcript variant 1NM_002562P2RX76.13E − 011.23
Purinergic receptor P2X, ligand-gated ion channel, 7, transcript variant 1NM_002562P2RX79.17E − 011.04

(o) Transient receptor potential channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Polycystic kidney disease 2 (autosomal dominant)NM_000297PKD27.48E − 071.79
Polycystic kidney disease 2 (autosomal dominant)NM_000297PKD22.38E − 051.98
Polycystic kidney disease 2-like 1NM_016112PKD2L11.29E − 03 4.66
Polycystic kidney disease 2-like 2NM_014386PKD2L21.94E − 011.49
Polycystic kidney disease 2-like 2NM_014386PKD2L27.43E − 011.19
Polycystic kidney disease 2-like 2NM_014386PKD2L26.74E − 011.09
Transient receptor potential cation channel, subfamily A, member 1NM_007332TRPA12.99E − 011.74
Transient receptor potential cation channel, subfamily A, member 1NM_007332TRPA15.64E − 022.70
Transient receptor potential cation channel, subfamily C, member 1NM_003304TRPC14.30E − 06 2.01
Transient receptor potential cation channel, subfamily C, member 3, transcript variant 2NM_003305TRPC31.12E − 07 5.78 2.45
Transient receptor potential cation channel, subfamily C, member 4, transcript variant alphaNM_016179TRPC43.25E − 07 25.38
Transient receptor potential cation channel, subfamily C, member 5NM_012471TRPC51.20E − 011.28
Transient receptor potential cation channel, subfamily C, member 6NM_004621TRPC61.21E − 012.33
Transient receptor potential cation channel, subfamily C, member 7, transcript variant 1NM_020389TRPC76.18E − 01−1.36
Transient receptor potential cation channel, subfamily M, member 1NM_002420TRPM12.29E − 011.31
Transient receptor potential cation channel, subfamily M, member 2, transcript variant 1NM_003307TRPM21.22E − 011.97
Transient receptor potential cation channel, subfamily M, member 2, transcript variant 1NM_003307TRPM25.04E − 022.53
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 7NM_206948TRPM33.04E − 09 10.69
Transient receptor potential cation channel, subfamily M, member 3 [Source: HGNC Symbol; Acc: 17992]ENST00000354500TRPM32.34E − 03 3.74
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 7NM_206948TRPM33.41E − 06 6.23
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 9NM_001007471TRPM37.23E − 011.13
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 9NM_001007471TRPM31.54E − 05 2.60
Transient receptor potential cation channel, subfamily M, member 4, transcript variant 1NM_017636TRPM43.72E − 02−1.89
Transient receptor potential cation channel, subfamily M, member 5NM_014555TRPM58.21E − 01−1.08
Transient receptor potential cation channel, subfamily M, member 6, transcript variant aNM_017662TRPM63.80E − 011.64
Transient receptor potential cation channel, subfamily M, member 6, transcript variant aNM_017662TRPM69.10E − 011.05
Transient receptor potential cation channel, subfamily M, member 6, transcript variant aNM_017662TRPM65.32E − 07 5.59
Transient receptor potential cation channel, subfamily M, member 6, transcript variant aNM_017662TRPM63.32E − 011.36
Transient receptor potential cation channel, subfamily M, member 7NM_017672TRPM72.16E − 02−1.25
Transient receptor potential cation channel, subfamily M, member 7NM_017672TRPM73.64E − 03−1.38
Transient receptor potential cation channel, subfamily M, member 8NM_024080TRPM82.04E − 011.89
Transient receptor potential cation channel, subfamily V, member 1, transcript variant 3NM_080706TRPV13.59E − 051.92
Transient receptor potential cation channel, subfamily V, member 1, transcript variant 3NM_080706TRPV14.14E − 05 2.25
Transient receptor potential cation channel, subfamily V, member 2NM_016113TRPV28.02E − 08 4.68
Transient receptor potential cation channel, subfamily V, member 3NM_145068TRPV34.64E − 011.35
Transient receptor potential cation channel, subfamily V, member 3NM_145068TRPV31.35E − 01−2.39
Transient receptor potential cation channel, subfamily V, member 4, transcript variant 2NM_147204TRPV44.33E − 011.39
Transient receptor potential cation channel, subfamily V, member 5, (cDNA clone MGC: 34269 IMAGE: 5186668)BC034740TRPV51.00E − 011.38
Transient receptor potential cation channel, subfamily V, member 5NM_019841TRPV53.14E − 01−1.40
Transient receptor potential cation channel, subfamily V, member 6NM_018646TRPV61.57E − 01−1.38

(p) Voltage-gated sodium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Sodium channel, voltage-gated, type I, alpha subunit, transcript variant 2NM_006920SCN1A1.98E − 011.54
Sodium channel, voltage-gated, type I, beta, transcript variant bNM_199037SCN1B9.95E − 01−1.00
Sodium channel, voltage-gated, type II, alpha subunit, transcript variant 1NM_021007SCN2A4.16E − 011.62 5.00
Sodium channel, voltage-gated, type II, betaNM_004588SCN2B3.61E − 01−1.58
Sodium channel, voltage-gated, type II, betaNM_004588SCN2B 8.16 E04 −2.41
Sodium channel, voltage-gated, type III, alpha subunit, transcript variant 1NM_006922SCN3A2.87E − 01−2.00 2.85
Sodium channel, voltage-gated, type III, alpha subunit, transcript variant 1NM_006922SCN3A1.89E − 011.49
Sodium channel, voltage-gated, type III, beta, transcript variant 1NM_018400SCN3B8.74E − 01−1.06 4.70
Sodium channel, voltage-gated, type III, beta, transcript variant 1NM_018400SCN3B1.57E − 01−1.46
Sodium channel, voltage-gated, type III, beta, transcript variant 1NM_018400SCN3B1.56E − 011.96
Sodium channel, voltage-gated, type IV, alpha subunitNM_000334SCN4A1.62E − 08 9.91
Sodium channel, voltage-gated, type IV, beta, transcript variant 1NM_174934SCN4B 3.25 E04 −3.66
Sodium channel, voltage-gated, type V, alpha subunit, transcript variant 1NM_198056SCN5A2.43E − 08 14.10
Sodium channel, voltage-gated, type V, alpha subunit, transcript variant 2NM_000335SCN5A4.93E − 021.95
Sodium channel, voltage-gated, type VII, alphaNM_002976SCN7A4.49E − 031.63
Sodium channel, voltage-gated, type VII, alphaNM_002976SCN7A2.07E − 011.72
Sodium channel, voltage gated, type VIII, alpha subunit, transcript variant 1NM_014191SCN8A1.89E − 09 15.61
Sodium channel, voltage gated, type VIII, alpha subunit, transcript variant 1NM_014191SCN8A4.06E − 07 11.23
Sodium channel, voltage-gated, type IX, alpha subunitNM_002977SCN9A4.08E − 08 11.51
Sodium channel, voltage-gated, type IX, alpha subunitNM_002977SCN9A1.62E − 011.66
Sodium channel, voltage-gated, type IX, alpha subunitNM_002977SCN9A3.38E − 03 2.57
Sodium channel, voltage-gated, type X, alpha subunitNM_006514SCN10A4.06E − 011.35
Sodium channel, voltage-gated, type XI, alpha subunitNM_014139SCN11A3.02E − 011.57
Sodium channel, voltage-gated, type XI, alpha subunit [Source: HGNC Symbol; Acc: 10583]ENST00000444237SCN11A8.83E − 031.94

(q) Nonvoltage-gated sodium channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Sodium channel, nonvoltage-gated 1 alpha, transcript variant 1NM_001038SCNN1A1.33E − 09 51.49 −21.13 −10.71
Sodium channel, nonvoltage-gated 1, betaNM_000336SCNN1B2.11E − 011.64
Sodium channel, nonvoltage-gated 1, betaNM_000336SCNN1B5.52E − 011.09
Sodium channel, nonvoltage-gated 1, delta, transcript variant 1NM_001130413SCNN1D8.43E − 021.49
Sodium channel, nonvoltage-gated 1, gammaNM_001039SCNN1G2.33E − 011.59
Gamma subunit of epithelial amiloride-sensitive sodium channelX87160SCNN1G3.99E − 011.27

(r) Two-pore channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Two-pore segment channel 1, transcript variant 1NM_001143819TPCN16.20E − 04−1.76
Two-pore segment channel 1, transcript variant 2NM_017901TPCN1 1.71 E03 −2.10
Two-pore segment channel 1, transcript variant 2NM_017901TPCN1 3.55 E04 −2.44
Two-pore segment channel 1, transcript variant 1NM_001143819TPCN18.06E − 03−1.83
Two-pore segment channel 2NM_139075TPCN25.06E − 01−1.15

(s) Zinc-activated ligand-gated ion channels

Gene nameAccession numberGene symbolPFold change Ker → hiPSCFold change hiPSC → NeuronFold change hiPSC → CM
Zinc-activated ligand-gated ion channelNM_180990ZACN9.24E − 021.45
  81 in total

1.  Developmental and functional nature of human iPSC derived motoneurons.

Authors:  Marianne Stockmann; Leonhard Linta; Karl J Föhr; Anja Boeckers; Albert C Ludolph; Georges F Kuh; Patrick T Udvardi; Christian Proepper; Alexander Storch; Alexander Kleger; Stefan Liebau; Tobias M Boeckers
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

Review 2.  Inwardly rectifying potassium channels: their structure, function, and physiological roles.

Authors:  Hiroshi Hibino; Atsushi Inanobe; Kazuharu Furutani; Shingo Murakami; Ian Findlay; Yoshihisa Kurachi
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

3.  Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2.

Authors:  S Signorini; Y J Liao; S A Duncan; L Y Jan; M Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

Review 4.  Possible involvement of TRP channels in cardiac hypertrophy and arrhythmia.

Authors:  Hiroyuki Watanabe; Kenji Iino; Takayoshi Ohba; Hiroshi Ito
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  Another member of the cyclic nucleotide-gated channel family, expressed in testis, kidney, and heart.

Authors:  M Biel; X Zong; M Distler; E Bosse; N Klugbauer; M Murakami; V Flockerzi; F Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Activation of transient receptor potential canonical 3 (TRPC3)-mediated Ca2+ entry by A1 adenosine receptor in cardiomyocytes disturbs atrioventricular conduction.

Authors:  Jessica Sabourin; Fabrice Antigny; Elodie Robin; Maud Frieden; Eric Raddatz
Journal:  J Biol Chem       Date:  2012-06-12       Impact factor: 5.157

7.  Transient receptor potential melastatin type 7 channel is critical for the survival of bone marrow derived mesenchymal stem cells.

Authors:  Henrique Cheng; Ji-Ming Feng; Marxa L Figueiredo; Hanjie Zhang; Piper L Nelson; Vanessa Marigo; Andreas Beck
Journal:  Stem Cells Dev       Date:  2010-09       Impact factor: 3.272

8.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

9.  Characterizing human ion channels in induced pluripotent stem cell-derived neurons.

Authors:  Alison Haythornthwaite; Sonja Stoelzle; Alexander Hasler; Andrea Kiss; Johannes Mosbacher; Michael George; Andrea Brüggemann; Niels Fertig
Journal:  J Biomol Screen       Date:  2012-08-24

10.  An SK3 channel/nWASP/Abi-1 complex is involved in early neurogenesis.

Authors:  Stefan Liebau; Julie Steinestel; Leonhard Linta; Alexander Kleger; Alexander Storch; Michael Schoen; Konrad Steinestel; Christian Proepper; Juergen Bockmann; Michael J Schmeisser; Tobias M Boeckers
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more
  6 in total

1.  Developmental HCN channelopathy results in decreased neural progenitor proliferation and microcephaly in mice.

Authors:  Anna Katharina Schlusche; Sabine Ulrike Vay; Niklas Kleinenkuhnen; Steffi Sandke; Rafael Campos-Martín; Marta Florio; Wieland Huttner; Achim Tresch; Jochen Roeper; Maria Adele Rueger; Igor Jakovcevski; Malte Stockebrand; Dirk Isbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

2.  Expression of Pluripotency Genes in Chondrocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells.

Authors:  Ewelina Stelcer; Katarzyna Kulcenty; Marcin Rucinski; Karol Jopek; Tomasz Trzeciak; Magdalena Richter; Joanna P Wroblewska; Wiktoria M Suchorska
Journal:  Int J Mol Sci       Date:  2018-02-12       Impact factor: 5.923

3.  Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes - A Tool to Study Neurodevelopmental Disorders as ADHD.

Authors:  Silvano Re; Asli Aybike Dogan; Dorit Ben-Shachar; Gregor Berger; Anna Maria Werling; Susanne Walitza; Edna Grünblatt
Journal:  Front Cell Neurosci       Date:  2018-09-25       Impact factor: 5.505

4.  Transcriptome Analysis Reveals That Alfalfa Promotes Rumen Development Through Enhanced Metabolic Processes and Calcium Transduction in Hu Lambs.

Authors:  Bin Yang; Hongwei Chen; Jiawen Cao; Bo He; Shanshan Wang; Yang Luo; Jiakun Wang
Journal:  Front Genet       Date:  2019-10-03       Impact factor: 4.599

Review 5.  Plucked human hair shafts and biomolecular medical research.

Authors:  Kevin Schembri; Christian Scerri; Duncan Ayers
Journal:  ScientificWorldJournal       Date:  2013-10-31

Review 6.  The Role of Kv7.2 in Neurodevelopment: Insights and Gaps in Our Understanding.

Authors:  Nina Dirkx; Francesco Miceli; Maurizio Taglialatela; Sarah Weckhuysen
Journal:  Front Physiol       Date:  2020-10-28       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.